Sana Biotechnology, Inc. — Q2 2023 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2023. Sana is a development-stage cell-engineering biotechnology company with no approved products and no product revenue.
Financial performance and position
- Revenue and margins: No product revenue was reported. The filing describes no meaningful operating margin for this pre-revenue business.
- Q2 2023: Operating expenses were $116.3 million and net loss was $114.0 million, or $0.59 per share, versus $72.9 million of expenses and a $72.5 million loss, or $0.39 per share, in Q2 2022. Q2 2023 expenses included $26.7 million of fair-value expense for success-payment and contingent-consideration liabilities; the comparable 2022 quarter included a $17.9 million gain.
- First half 2023: Operating expenses were $200.3 million and net loss was $196.1 million, or $1.02 per share, compared with $104.6 million of expenses and a $103.9 million loss, or $0.56 per share, in first-half 2022. The $100.2 million year-over-year increase in revaluation expense was a major driver of the higher loss.
- Operating costs: First-half research and development expense fell to $140.2 million from $145.2 million, mainly due to lower technology-licensing and third-party manufacturing costs. General and administrative expense was $33.3 million, compared with $32.7 million.
- Cash flow: First-half operating cash use was $138.1 million, versus $149.2 million in 2022. Investing activities provided $105.4 million, primarily reflecting marketable-security maturities net of purchases; financing provided $29.7 million, including ATM offering proceeds. Cash, cash equivalents, and restricted cash decreased $3.0 million.
- Liquidity and debt: At June 30, cash, cash equivalents, and marketable securities totaled $325.9 million; accumulated deficit was $1.3 billion. Management stated that current resources should fund working capital and capital expenditures for at least the next 12 months. Sana had no debt outstanding.
- Other obligations: Total liabilities were $352.1 million, including $113.1 million of operating lease liabilities and $198.2 million of fair-value contingent-consideration and success-payment liabilities. Undiscounted operating lease payments totaled $236.1 million.
Material changes versus the prior comparable period
- Net loss increased by $41.5 million in Q2 and $92.2 million in the first half. The comparison was significantly affected by swings in non-cash fair-value remeasurements: first-half 2023 had $26.8 million of expense, while first-half 2022 had a $73.4 million gain.
- First-half R&D expense declined by $5.0 million, while operating cash use improved by $11.1 million.
- Liquidity in cash, cash equivalents, and marketable securities declined from $434.0 million at December 31, 2022 to $325.9 million at June 30, 2023. Sana raised $27.6 million net under its ATM facility through June 30, from sales of 4.7 million shares.
- Shares outstanding rose to 196.9 million at June 30, 2023 from 191.0 million at year-end 2022.
Outlook, risks, and unusual items
- Management expected operating losses and expenses to remain relatively flat over the next few years, with potential increases over the longer term if clinical development expands. Additional financing will likely be needed; equity financing could dilute shareholders, and financing may not be available on acceptable terms.
- Clinical and regulatory outlook stated in the filing: Sana expected initial clinical data from its SC291 CAR T program and an investigator-sponsored islet-cell trial in 2023; it planned IND submissions for SC262 and SG299 in 2023, with potential INDs for SC255 in 2024 and SC451 as early as 2024. These were forward-looking expectations, not reported outcomes.
- Key risks include uncertain clinical safety and efficacy, regulatory delays, complex cell-therapy manufacturing and reliance on third parties, supply-chain constraints, intellectual-property dependence, and the need for additional capital. The filing also cites inflation, interest-rate and market volatility, and geopolitical risks.
- Potential Cobalt obligations include up to $500 million of development-milestone contingent consideration and a separate success payment of up to $500 million; Harvard success payments may total up to $175 million. None of the success payments had been triggered as of June 30, 2023. These maximum amounts are contingent, not amounts currently due.
- Fair-value remeasurements depend on factors including stock price, market capitalization, development milestones, and valuation assumptions, and can materially affect GAAP losses without corresponding current-period cash payments.
- Sana planned to establish manufacturing in Bothell rather than Fremont and intended to sublease or terminate its Fremont lease. The Bothell lease runs through 2039; delays or costs in developing manufacturing capacity remain risks.
- No material legal proceedings were reported. Management concluded disclosure controls were effective at a reasonable-assurance level, with no material quarterly change in internal control over financial reporting.
Important facts for investors to verify
- Whether SC291 and the investigator-sponsored islet-cell trial produced the expected 2023 data, and what the results show about safety and efficacy.
- Progress and timing of the planned SC262 and SG299 IND submissions and later-stage program timelines.
- Cash burn, actual runway versus management’s at-least-12-month estimate, and the potential need for further financing or ATM share sales.
- Changes in the fair value, assumptions, and potential payment triggers for Cobalt and Harvard obligations; distinguish recorded liabilities from maximum contingent payments.
- Progress, cost, and timing of the Bothell manufacturing buildout and resolution of the Fremont lease.